This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
View filing at SEC.gov →5 most recent filings and news items mentioning APGE. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/APGE/news?limit=20"
Pull APGE filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayThis IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
View filing at SEC.gov →AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share, totaling approximately $10.9 billion in equity value. The acquisition adds a clinical-stage immunology pipeline focused on inflammatory and immunological diseases including atopic dermat
View filing at SEC.gov →AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
View filing at SEC.gov →Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences providing up to $1.3 billion in non-dilutive capital, including $800 million in synthetic royalty and $500 million in senior debt, to fund Phase 3 development and commercialization of
View filing at SEC.gov →Apogee announced positive 16-week Part B induction dose optimization results from its Phase 2 APEX trial of zumilokibart, with 65.9% of mid-dose patients achieving EASI-75 endpoints. The company plans to advance the mid-dose into Phase 3 trials in 2H 2026 and secured strategic fi
View filing at SEC.gov →